On Dec 8, 2018 AC Immune SA (NASDAQ:ACIU) Shorts Strengthened By 0.88%

Change of 0.88% for AC Immune SA (NASDAQ:ACIU)’s shorted shares was recorded. In December was published ACIU’s total 1.41M shorted shares by FINRA. The 1.39M previous shares are up with 0.88%. Former ACIU’s position will need 9 days to restore. It has 153,000 average volume. AC Immune SA’s shorted shares float is 4.26%.

Ticker’s shares touched $11.15 during the last trading session after 4.60% change.Currently AC Immune SA is downtrending after 19.43% change in last December 8, 2017. ACIU has 76,957 shares volume. ACIU underperformed by 35.05% the S&P 500.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.The firm is valued at $751.09 million. The Company’s SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s , ParkinsonÂ’s, down syndrome, and glaucoma diseases.Last it reported negative earnings. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies.

For more AC Immune SA (NASDAQ:ACIU) news posted recently go to: Nasdaq.com, Seekingalpha.com, Globenewswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “What’s in the Cards for Puma Biotech (PBYI) in Q2 Earnings? – Nasdaq” posted on August 07, 2018, “AC Immune -12% as Biogen’s Alzheimer’s data fails to impress – Seeking Alpha” on July 25, 2018, “AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD’S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIMER’S DISEASE-LIKE CHARACTERISTICS IN INDIVIDUALS WITH DOWN SYNDROME – GlobeNewswire” with a publish date: September 12, 2017, “Your Daily Pharma Scoop: Biogen Rallies, AC Immune Goes Up, Not Everyone On Board With Biogen – Seeking Alpha” and the last “AC Immune prices its 10M equity offering, shares up 1.4% premarket – Seeking Alpha” with publication date: July 19, 2018.

AC Immune SA (NASDAQ:ACIU) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.